Pfizer. has filed a patent for multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units constructed in a site-specific manner using ‘orthogonal’ deprotection and drug loading. The Protected Linking Assembly Units enable the construction of MD-ADCs and LA Units. GlobalData’s report on Pfizer gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Pfizer Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Pfizer, Cancer treatment biomarkers was a key innovation area identified from patents. Pfizer's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Multi-drug antibody drug conjugates with site-specific construction

Source: United States Patent and Trademark Office (USPTO). Credit: Pfizer Inc

The patent application US20240033372A1 discloses a Drug Linking Assembly Unit represented by formulas (Ia), (IIa), (IIIa), or (IVa). The assembly unit includes specific components such as succinimido groups in L1 and L2, amino acids in X, X1, X2, Q1, and Q2, and a maleimido group in T, which can be a self-stabilizing linker or a MDPr-vc linker. The assembly unit can be used for linking anticancer agents like MMAE, MMAF, camptothecin, and doxorubicin, with complementary activity profiles, to a partitioning agent like polyethylene glycol or cyclodextrin.

Furthermore, the Drug Linking Assembly Unit described in the patent application allows for the attachment of anticancer agents such as MMAE, Auristatin T, MMAF, and Dolastatin 10, or a combination of MMAE, camptothecin, Superdox, Dolastatin 10, Vinblastine, and Ciprofloxacin to cysteine molecules via specific linkers. The assembly unit also includes a terminal maleimido group represented by specific formulas, providing a versatile platform for drug conjugation. Additionally, the assembly unit features a succinimido group in R23, enhancing the stability and efficacy of the drug conjugates. The patent application covers a range of drug linking possibilities and configurations for targeted drug delivery applications.

To know more about GlobalData’s detailed insights on Pfizer, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies